PubRank

Douglas D Richman

Author PubWeight™ 285.91‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008 11.72
2 Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002 10.03
3 Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002 9.70
4 The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010 9.61
5 Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010 9.26
6 Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012 8.94
7 Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006 7.49
8 Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005 5.75
9 Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002 5.56
10 Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008 5.20
11 Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003 4.51
12 Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 2007 4.45
13 Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013 4.26
14 Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013 4.05
15 Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A 2005 3.94
16 Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005 3.93
17 Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004 3.74
18 Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008 3.66
19 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011 3.66
20 Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 2013 3.58
21 Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One 2013 3.53
22 Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009 3.52
23 Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2004 3.20
24 Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006 3.06
25 Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008 3.04
26 Update of the Drug Resistance Mutations in HIV-1. Top HIV Med 2008 2.91
27 Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010 2.91
28 Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol 2005 2.83
29 Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis 2013 2.82
30 Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007 2.79
31 Evaluation of an HIV nucleic acid testing program with automated Internet and voicemail systems to deliver results. Ann Intern Med 2010 2.69
32 Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003 2.54
33 Adaptation to different human populations by HIV-1 revealed by codon-based analyses. PLoS Comput Biol 2006 2.48
34 Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol 2006 2.33
35 HIV superinfection. J Infect Dis 2005 2.20
36 Whither or wither microbicides? Science 2008 2.17
37 Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013 2.11
38 Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis 2008 2.08
39 Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology 2006 2.07
40 Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS 2003 2.05
41 Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 2005 2.04
42 Role of seminal shedding of herpesviruses in HIV Type 1 Transmission. J Infect Dis 2012 1.99
43 Incidence of HIV superinfection following primary infection. JAMA 2004 1.92
44 A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 2002 1.83
45 A public health model for the molecular surveillance of HIV transmission in San Diego, California. AIDS 2009 1.81
46 Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains. J Virol 2005 1.77
47 The origins of sexually transmitted HIV among men who have sex with men. Sci Transl Med 2010 1.76
48 Drug resistance mutations in HIV-1. Top HIV Med 2003 1.72
49 Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2007 1.72
50 Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther 2012 1.71
51 The global transmission network of HIV-1. J Infect Dis 2013 1.68
52 Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med 2006 1.65
53 Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. J Infect Dis 2007 1.64
54 Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med 2004 1.62
55 HIV-specific cytotoxic T cells from long-term survivors select a unique T cell receptor. J Exp Med 2004 1.60
56 Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain 2006 1.60
57 Herpes viruses and HIV-1 drug resistance mutations influence the virologic and immunologic milieu of the male genital tract. AIDS 2013 1.60
58 Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection. J Infect Dis 2007 1.59
59 SMM-chemokines: a class of unnatural synthetic molecules as chemical probes of chemokine receptor biology and leads for therapeutic development. Chem Biol 2006 1.58
60 Herpes simplex virus 2 serostatus and viral loads of HIV-1 in blood and semen as risk factors for HIV transmission among men who have sex with men. AIDS 2008 1.55
61 Associations between virologic and immunologic dynamics in blood and in the male genital tract. J Virol 2011 1.55
62 Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir Ther 2003 1.53
63 Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men. Clin Infect Dis 2013 1.53
64 Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus. AIDS 2003 1.52
65 HIV drug resistance acquired through superinfection. AIDS 2005 1.52
66 Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. J Virol 2005 1.52
67 Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol 2011 1.44
68 Dynamics of T cell responses in HIV infection. J Immunol 2002 1.44
69 Minority variants of drug-resistant HIV. J Infect Dis 2010 1.44
70 A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. HIV Clin Trials 2003 1.42
71 Drug resistance mutations in HIV-1. Top HIV Med 2004 1.37
72 The use of pooled viral load testing to identify antiretroviral treatment failure. AIDS 2009 1.37
73 Phylogenetic analysis of population-based and deep sequencing data to identify coevolving sites in the nef gene of HIV-1. Mol Biol Evol 2009 1.37
74 Pooled nucleic acid testing to detect antiretroviral treatment failure in Mexico. J Acquir Immune Defic Syndr 2011 1.31
75 Adaptation to human populations is revealed by within-host polymorphisms in HIV-1 and hepatitis C virus. PLoS Pathog 2007 1.31
76 Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retroviruses 2005 1.24
77 Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy. J Acquir Immune Defic Syndr 2002 1.21
78 Interferon gene expression following HIV type 1 infection of monocyte-derived macrophages. AIDS Res Hum Retroviruses 2004 1.13
79 Incidence and prevalence of intrasubtype HIV-1 dual infection in at-risk men in the United States. J Infect Dis 2013 1.13
80 Evolution of the interferon alpha gene family in eutherian mammals. Gene 2007 1.12
81 Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology 2008 1.11
82 Cytomegalovirus DNA in semen and blood is associated with higher levels of proviral HIV DNA. J Infect Dis 2012 1.10
83 Clinical, virologic, and immunologic correlates of HIV-1 intraclade B dual infection among men who have sex with men. AIDS 2012 1.10
84 Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection. AIDS 2013 1.10
85 HIV-1 clade B pol evolution following primary infection. PLoS One 2013 1.07
86 Polyclonal proliferation and apoptosis of CCR5+ T lymphocytes during primary human immunodeficiency virus type 1 infection: regulation by interleukin (IL)-2, IL-15, and Bcl-2. J Infect Dis 2003 1.03
87 Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS 2003 1.02
88 Optimizing peptide matrices for identifying T-cell antigens. Cytometry A 2008 1.00
89 The prostate as a reservoir for HIV-1. AIDS 2004 0.96
90 A computer-based, image-analysis method to quantify HIV-1 infection in a single-cycle infectious center assay. J Virol Methods 2006 0.95
91 Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. AIDS Res Hum Retroviruses 2010 0.95
92 Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells. AIDS 2013 0.94
93 The Use of High Performance Liquid Chromatography to Speciate and Characterize the Epidemiology of Mycobacteria. Lab Med 2011 0.94
94 Pleocytosis is associated with disruption of HIV compartmentalization between blood and cerebral spinal fluid viral populations. Virology 2008 0.94
95 The efficiency of single genome amplification and sequencing is improved by quantitation and use of a bioinformatics tool. J Virol Methods 2009 0.94
96 Differential gene expression in HIV-infected individuals following ART. Antiviral Res 2013 0.94
97 Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection. J Virol 2004 0.93
98 Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top HIV Med 2009 0.93
99 Virologic correlates of anti-CMV IgG levels in HIV-1-infected men. J Infect Dis 2013 0.93
100 New assays for monitoring residual HIV burden in effectively treated individuals. Curr Opin HIV AIDS 2013 0.93
101 Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(+) T-cell death. J Virol 2002 0.91
102 A combined screening platform for HIV treatment failure and resistance. PLoS One 2012 0.91
103 Broadly increased sensitivity to cytotoxic T lymphocytes resulting from Nef epitope escape mutations. J Immunol 2003 0.91
104 Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance. AIDS 2008 0.89
105 Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression. AIDS 2002 0.89
106 Probing chelation motifs in HIV integrase inhibitors. Proc Natl Acad Sci U S A 2012 0.87
107 Dynamics of viral evolution and neutralizing antibody response after HIV-1 superinfection. J Virol 2013 0.86
108 Codon volatility does not reflect selective pressure on the HIV-1 genome. Virology 2005 0.86
109 Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy. Antimicrob Agents Chemother 2009 0.86
110 Herpes simplex virus type 2 acquisition during recent HIV infection does not influence plasma HIV levels. J Acquir Immune Defic Syndr 2008 0.86
111 A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS 2005 0.86
112 Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol 2012 0.85
113 Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients. J Virol 2007 0.85
114 Impact of seminal cytomegalovirus replication on HIV-1 dynamics between blood and semen. J Med Virol 2012 0.85
115 Gene expression before HAART initiation predicts HIV-infected individuals at risk of poor CD4+ T-cell recovery. AIDS 2010 0.85
116 Antibody responses in primary HIV-1 infection. Curr Opin HIV AIDS 2008 0.85
117 Measuring the latent reservoir in vivo. J Clin Invest 2016 0.84
118 Broad advances in understanding HIV resistance to antiretrovirals: report on the XVII International HIV Drug Resistance Workshop. Antivir Ther 2008 0.83
119 Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure. AIDS 2010 0.83
120 Evaluation of a highly sensitive qualitative human immunodeficiency virus type 1 (HIV-1) RNA assay for detection of HIV-1 suppression. J Clin Microbiol 2008 0.82
121 Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study). Clin Infect Dis 2005 0.82
122 HIV migration between blood and cerebrospinal fluid or semen over time. J Infect Dis 2013 0.82
123 No evidence of posttreatment control after early initiation of antiretroviral therapy. AIDS 2015 0.82
124 Select host restriction factors are associated with HIV persistence during antiretroviral therapy. AIDS 2015 0.81
125 Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment. Virology 2012 0.81
126 Sexual transmission of predicted CXCR4-tropic HIV-1 likely originating from the source partner's seminal cells. Virology 2012 0.80
127 A novel codon insert in protease of clade B HIV type 1. AIDS Res Hum Retroviruses 2009 0.80
128 HIV downregulates interferon-stimulated genes in primary macrophages. J Interferon Cytokine Res 2012 0.80
129 Poor agreement between 2 assays for measuring low levels of HIV-1 viral load. Clin Infect Dis 2009 0.80
130 Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance. Virology 2009 0.79
131 Cell-intrinsic mechanism involving Siglec-5 associated with divergent outcomes of HIV-1 infection in human and chimpanzee CD4 T cells. J Mol Med (Berl) 2012 0.78
132 Using ultradeep pyrosequencing to study HIV-1 coreceptor usage in primary and dual infection. J Infect Dis 2013 0.78
133 Prevalence of Transmitted HIV Drug Resistance Among Recently Infected Persons in San Diego, CA 1996-2013. J Acquir Immune Defic Syndr 2016 0.78
134 Inhibition of HIV-1 by octadecyloxyethyl esters of (S)-[3-hydroxy-2-(phosphonomethoxy)propyl] nucleosides and evaluation of their mechanism of action. Antimicrob Agents Chemother 2011 0.77
135 A synthetic bivalent ligand of CXCR4 inhibits HIV infection. Biochem Biophys Res Commun 2013 0.77
136 Novel codon insert in HIV type 1 clade B reverse transcriptase associated with low-level viremia during antiretroviral therapy. AIDS Res Hum Retroviruses 2013 0.77
137 Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel. Top HIV Med 2003 0.76
138 HIV and hepatitis virus resistance to antivirals: review of data from the XIX International HIV and Hepatitis Virus Drug Resistance Workshop and curative strategies. Antivir Ther 2011 0.76
139 HIV-associated neurocognitive disorder is associated with HIV-1 dual infection. AIDS 2016 0.75
140 Antibody response to Achromobacter xylosoxidans during HIV infection is associated with lower CD4 levels and increased lymphocyte activation. Clin Vaccine Immunol 2013 0.75
141 Advances in the management of HIV-HBV coinfection. Antivir Ther 2007 0.75
142 A plea for justice for jailed medical workers. Science 2006 0.75
143 Preface. Curr Top Microbiol Immunol 2015 0.75
144 Increased HIV-1 superinfection risk in carriers of specific human leukocyte antigen alleles. AIDS 2017 0.75
145 Progress in basic and clinical research on HIV resistance: report on the XVIII International HIV Drug Resistance Workshop. Antivir Ther 2009 0.75